Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells

被引:22
作者
Chu, Carolyn [1 ]
Armenia, Daniele [2 ]
Walworth, Charles [3 ]
Santoro, Maria M. [4 ]
Shafer, Robert W. [5 ]
机构
[1] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA
[2] St Camillus Int Univ Hlth Sci, UniCamillus, Rome, Italy
[3] Lab Corp Monogram Biosci, South San Francisco, CA USA
[4] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
[5] Stanford Univ, Dept Med, Div Infect Dis, Stanford, CA 94305 USA
关键词
antiviral therapy; DNA sequencing; HIV-1; peripheral blood mononuclear cells; provirus; adaptive mutations; drug resistance evolution; LOW-LEVEL VIREMIA; CD4(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; RILPIVIRINE/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE; DRUG-RESISTANCE; HIV-1-INFECTED PATIENTS; PROVIRAL DNA; LATENT RESERVOIR; TREATMENT INTERRUPTION; VIROLOGICAL FAILURE;
D O I
10.1128/cmr.00052-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear cell (PBMC) HIV-1 DNA consists of recently produced nonintegrated virus DNA while in patients with prolonged virological suppression (VS) on antiretroviral therapy (ART), most PBMC HIV-1 DNA consists of proviral DNA produced months to years earlier. Drug-resistance mutations (DRMs) in PBMCs are more likely to coexist with ancestral wild-type virus populations than they are in plasma, explaining why next-generation sequencing is particularly useful for the detection of PBMC-associated DRMs. In patients with ongoing high levels of active virus replication, the DRMs detected in PBMCs and in plasma are usually highly concordant. However, in patients with lower levels of virus replication, it may take several months for plasma virus DRMs to reach detectable levels in PBMCs. This time lag explains why, in patients with VS, PBMC genotypic resistance testing (GRT) is less sensitive than historical plasma virus GRT, if previous episodes of virological failure and emergent DRMs were either not prolonged or not associated with high levels of plasma viremia. Despite the increasing use of PBMC GRT in patients with VS, few studies have examined the predictive value of DRMs on the response to a simplified ART regimen. In this review, we summarize what is known about PBMC HIV-1 DNA dynamics, particularly in patients with suppressed plasma viremia, the methods used for PBMC HIV-1 GRT, and the scenarios in which PBMC GRT has been used clinically. HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear cell (PBMC) HIV-1 DNA consists of recently produced nonintegrated virus DNA while in patients with prolonged virological suppression (VS) on antiretroviral therapy (ART), most PBMC HIV-1 DNA consists of proviral DNA produced months to years earlier.
引用
收藏
页数:30
相关论文
共 238 条
[1]   Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment [J].
Aamer, Hadega A. ;
McClure, Jan ;
Ko, Daisy ;
Maenza, Janine ;
Collier, Ann C. ;
Coombs, Robert W. ;
Mullins, James, I ;
Frenkel, Lisa M. .
PLOS PATHOGENS, 2020, 16 (08)
[2]   The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation [J].
Abrahams, Melissa-Rose ;
Joseph, Sarah B. ;
Garrett, Nigel ;
Tyers, Lynn ;
Moeser, Matthew ;
Archin, Nancie ;
Council, Olivia D. ;
Matten, David ;
Zhou, Shuntai ;
Doolabh, Deelan ;
Anthony, Colin ;
Goonetilleke, Nilu ;
Karim, Salim Abdool ;
Margolis, David M. ;
Pond, Sergei Kosakovsky ;
Williamson, Carolyn ;
Swanstrom, Ronald .
SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (513)
[3]   Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho [J].
Amstutz, Alain ;
Nsakala, Bienvenu Lengo ;
Vanobberghen, Fiona ;
Muhairwe, Josephine ;
Glass, Tracy Renee ;
Namane, Tilo ;
Mpholo, Tian ;
Battegay, Manuel ;
Klimkait, Thomas ;
Labhardt, Niklaus Daniel .
PLOS MEDICINE, 2020, 17 (09)
[4]  
Andreatta K, 2019, J ANTIMICROB CHEMOTH, V74, P3555, DOI 10.1093/jac/dkz347
[5]  
[Anonymous], 2021, Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV
[6]   HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia [J].
Armenia, D. ;
Fabeni, L. ;
Alteri, C. ;
Di Pinto, D. ;
Di Carlo, D. ;
Bertoli, A. ;
Gori, C. ;
Carta, S. ;
Fedele, V. ;
Forbici, F. ;
D'Arrigo, R. ;
Svicher, V. ;
Berno, G. ;
Pizzi, D. ;
Nicastri, E. ;
Sarmati, L. ;
Pinnetti, C. ;
Ammassari, A. ;
D'Offizi, G. ;
Latini, A. ;
Andreoni, M. ;
Antinori, A. ;
Ceccherini-Silberstein, F. ;
Perno, C. F. ;
Santoro, M. M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (06) :1865-1873
[7]   Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV [J].
Armenia, Daniele ;
Santoro, Maria Mercedes ;
Bellocchi, Maria Concetta ;
Carioti, Luca ;
Galli, Laura ;
Galli, Andrea ;
Scutari, Rossana ;
Salsi, Eleonora ;
Mussini, Cristina ;
Sterrantino, Gaetana ;
Calza, Leonardo ;
Rossetti, Barbara ;
Zazzi, Maurizio ;
Castagna, Antonella .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (01)
[8]   Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment [J].
Armenia, Daniele ;
Zaccarelli, Mauro ;
Borghi, Vanni ;
Gennari, William ;
Di Carlo, Domenico ;
Giannetti, Alberto ;
Forbici, Federica ;
Bertoli, Ada ;
Gori, Caterina ;
Fabeni, Lavinia ;
Pinnetti, Carmela ;
Marocco, Raffaella ;
Latini, Alessandra ;
Ceccherini-Silberstein, Francesca ;
Mastroianni, Claudio Maria ;
Mussini, Cristina ;
Antinori, Andrea ;
Perno, Carlo Federico ;
Santoro, Maria Mercedes .
JOURNAL OF CLINICAL VIROLOGY, 2018, 104 :61-64
[9]   Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study [J].
Assoumou, L. ;
Charpentier, C. ;
Recordon-Pinson, P. ;
Grude, M. ;
Pallier, C. ;
Morand-Joubert, L. ;
Fafi-Kremer, S. ;
Krivine, A. ;
Montes, B. ;
Ferre, V. ;
Bouvier-Alias, M. ;
Plantier, J. -C. ;
Izopet, J. ;
Trabaud, M. -A. ;
Yerly, S. ;
Dufayard, J. ;
Alloui, C. ;
Courdavault, L. ;
Le Guillou-Guillemette, H. ;
Maillard, A. ;
Amiel, C. ;
Vabret, A. ;
Roussel, C. ;
Vallet, S. ;
Guinard, J. ;
Mirand, A. ;
Beby-Defaux, A. ;
Barin, F. ;
Allardet-Servent, A. ;
Ait-Namane, R. ;
Wirden, M. ;
Delaugerre, C. ;
Calvez, V. ;
Chaix, M. -L. ;
Descamps, D. ;
Reigadas, S. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (06) :1769-1773
[10]   A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control [J].
Assoumou, Lambert ;
Weiss, Laurence ;
Piketty, Christophe ;
Burgard, Marianne ;
Melard, Adeline ;
Girard, Pierre-Marie ;
Rouzioux, Christine ;
Costagliola, Dominique .
AIDS, 2015, 29 (15) :2003-2007